<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04762459</url>
  </required_header>
  <id_info>
    <org_study_id>YX-L-202105</org_study_id>
    <nct_id>NCT04762459</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection</brief_title>
  <acronym>APEX</acronym>
  <official_title>Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for EGFR Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection: A Multicenter, Randomized Controlled, Open-label Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu Hansoh Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, open label, phase III study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, open label, phase III study assessing the efficacy and&#xD;
      safety of Almonertinib combined with or without chemotherapy as an adjuvant treatment in&#xD;
      patients with epidermal growth factor receptor (EGFR) mutation positive stage II-IIIA&#xD;
      non-squamous NSCLC following complete tumour resection: Eligible patients will be randomized&#xD;
      to receive either Almonertinib alone (110mg, po, once daily) or Almonertinib (110mg, po, once&#xD;
      daily) plus pemetrexed (500mg/m2, iv) and cisplatin (500mg/m2, iv) or pemetrexed (500mg/m2,&#xD;
      iv) plus cisplatin (500mg/m2, iv) in a 3:2:1 ratio.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">May 2029</completion_date>
  <primary_completion_date type="Anticipated">May 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>Defined as the time from the date of randomization until the date of disease recurrence or death (by any cause in the absence of recurrence)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>Defined as the proportion of patients alive and disease free at 2, 3 ,4and 5 years, respectively, estimated from Kaplan Meier plots of the primary endpoint of DFS at the time of the primary analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Start of study drug to Survival Endpoint through study completion, an average of 5 years, assessed up to 100 months</time_frame>
    <description>Defined as the time from the date of randomization until date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient health-related quality of life and symptoms (HRQoL) by SF-36v2 Health Survey</measure>
    <time_frame>From date of randomization until treatment completion or discontinuation, assessed up to 100 months</time_frame>
    <description>Defined as a patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section and the scores range from 0-100. A score of 0 is equivalent to maximum disability and a score of 100 is equivalent to no disability.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>From date of randomization until 28 days after treatment completion</time_frame>
    <description>AEs graded by CTCAE version 4.0</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">606</enrollment>
  <condition>Non-small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Almonertinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Almonertinib 110 mg A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: The patient continues to receive treatment until the disease progresses or reaches termination criteria. The overall treatment last for 3 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Almonertinib/Pemetrexed/Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Almonertinib 110 mg Drug: Pemetrexed 500 mg/m² IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.&#xD;
Drug: Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.&#xD;
A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: The patient continues to receive treatment until the disease progresses or reaches termination criteria. The overall treatment last for 3 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pemetrexed/Cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Pemetrexed 500 mg/m² IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.&#xD;
Drug: Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.&#xD;
A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: The patient continues to receive treatment until the disease progresses or reaches termination criteria. If disease progresses during the treatment period and conditions required for the cross-treatment are met according to the assessment process, the patient can start to receive the open cross-treatment of Almonertinib. The overall treatment last for 3 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Almonertinib</intervention_name>
    <description>Almonertinib 110mg PO once daily</description>
    <arm_group_label>Almonertinib</arm_group_label>
    <arm_group_label>Almonertinib/Pemetrexed/Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>500 milligrams per square meter (mg/m²) Pemetrexed</description>
    <arm_group_label>Almonertinib/Pemetrexed/Cisplatin</arm_group_label>
    <arm_group_label>Pemetrexed/Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>75mg/m² Cisplatin taken intravenously (IV) once every 3 weeks concurrently</description>
    <arm_group_label>Almonertinib/Pemetrexed/Cisplatin</arm_group_label>
    <arm_group_label>Pemetrexed/Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient who meets all of the following inclusion criteria will qualify for entry&#xD;
             into the study:&#xD;
&#xD;
               1. Male or female, aged at least 18 years.&#xD;
&#xD;
               2. Histologically confirmed diagnosis of primary non small lung cancer (NSCLC) on&#xD;
                  predominantly non-squamous histology.&#xD;
&#xD;
               3. Brain examination must be done prior to surgery as it is considered standard of&#xD;
                  care.&#xD;
&#xD;
               4. Patients must be classified post-operatively as Stage II-IIIA on the basis of&#xD;
                  pathologic criteria.&#xD;
&#xD;
               5. Confirmation by the central laboratory that the tumour harbours one of the 2&#xD;
                  common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del,&#xD;
                  L858R), either alone or in combination with other EGFR mutations including T790M.&#xD;
&#xD;
               6. Providing paraffin embedded section(10-15sheets),wax blocks or fresh frozen&#xD;
                  tissues.&#xD;
&#xD;
               7. Complete surgical resection of the primary NSCLC is mandatory. All gross disease&#xD;
                  must have been removed at the end of surgery. All surgical margins of resection&#xD;
                  must be negative for tumour.&#xD;
&#xD;
               8. World Health Organization Performance Status of 0 to 1.&#xD;
&#xD;
               9. Women of childbearing age should take appropriate contraceptive measures from&#xD;
                  screening to 3 months after stopping the study treatment and should not&#xD;
                  breastfeed. Before starting the administration, the pregnancy test was negative.&#xD;
&#xD;
              10. Male patients should be willing to use barrier contraception from screening to&#xD;
                  stopping study treatment for 3 months.(i.e., condoms).&#xD;
&#xD;
              11. For inclusion in study, patient must provide a written informed consent.&#xD;
&#xD;
              12. ≤10 weeks between surgery and randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any patient who meets any of the following exclusion criteria will not qualify for&#xD;
             entry into the study:&#xD;
&#xD;
               1. Treatment with any of the following:&#xD;
&#xD;
                    1. Pre-operative or post-operative or planned radiation therapy for the current&#xD;
                       lung cancer&#xD;
&#xD;
                    2. Pre-operative (neo-adjuvant) platinum based or other chemotherapy&#xD;
&#xD;
                    3. Prior treatment with neoadjuvant or adjuvant EGFR-TKI at any time&#xD;
&#xD;
                    4. Any other anti-tumor treatment for lung cancer(Including proprietary Chinese&#xD;
                       patent medicine with anti-tumor effects and anti-tumor immunotherapy, etc.)&#xD;
&#xD;
                    5. Major surgery (excluding placement of vascular access) within 4 weeks of the&#xD;
                       first dose of study drug.&#xD;
&#xD;
                    6. Treatment with an investigational drug within five half-lives of the&#xD;
                       compound or any of its related material.&#xD;
&#xD;
                    7. Medications that are predominantly CYP3A4 strong inhibitors or inducers or&#xD;
                       sensitive substrates of CYP3A4 with a narrow therapeutic range within 7 days&#xD;
                       of the first dose of study drug..&#xD;
&#xD;
               2. Patients who have had only segmentectomies or wedge resections&#xD;
&#xD;
               3. History of other malignancies, except: adequately treated non-melanoma skin&#xD;
                  cancer, curatively treated in-situ cancer, or other solid tumours curatively&#xD;
                  treated with no evidence of disease for &gt; 5 years following the end of treatment.&#xD;
&#xD;
               4. Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the&#xD;
                  time of starting study treatment with the exception of alopecia and Grade 2,&#xD;
                  prior platinum-therapy related neuropathy.&#xD;
&#xD;
               5. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled&#xD;
                  hypertension and active bleeding diatheses; or active infection including&#xD;
                  hepatitis B, hepatitis C and human immunodeficiency virus (HIV).&#xD;
&#xD;
               6. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to&#xD;
                  swallow the formulated product, or previous significant bowel resection that&#xD;
                  would preclude adequate absorption of Almonertinib.&#xD;
&#xD;
               7. Any of the following cardiac criteria:&#xD;
&#xD;
                    1. Mean resting corrected QT interval (QTc) &gt; 470 ms obtained from 3&#xD;
                       electrocardiograms (ECGs), using the screening clinic's ECG machine and&#xD;
                       Fridericia's formula for QT interval correction (QTcF).&#xD;
&#xD;
                    2. Any clinically important abnormalities in rhythm, conduction, or morphology&#xD;
                       of the resting ECG (e.g., complete left bundle branch block, third-degree&#xD;
                       heart block, second-degree heart block, PR interval &gt; 250 ms).&#xD;
&#xD;
                    3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic&#xD;
                       events, such as heart failure, hypokalemia, congenital long QT syndrome,&#xD;
                       family history of long QT syndrome, or unexplained sudden death under 40&#xD;
                       years of age in first degree relatives or any concomitant medication known&#xD;
                       to prolong the QT interval.&#xD;
&#xD;
               8. Past medical history of ILD, drug-induced ILD, radiation pneumonitis which&#xD;
                  required steroid treatment, or any evidence of clinically active ILD.&#xD;
&#xD;
               9. Inadequate bone marrow reserve or organ function.&#xD;
&#xD;
              10. History of hypersensitivity to any active or inactive ingredient of Almonertinib,&#xD;
                  or to drugs with a similar chemical structure or class to Almonertinib.&#xD;
&#xD;
              11. Patients who are allergic to pemetrexed or any other ingredients in the&#xD;
                  preparation, cisplatin or other platinum-containing compounds.&#xD;
&#xD;
              12. Patients with contraindications of pemetrexed and cisplatin.&#xD;
&#xD;
              13. Any severe and uncontrolled ocular disease that may, in the ophthalmologist's&#xD;
                  opinion, present a specific risk to the patient's safety.&#xD;
&#xD;
              14. Judgment by the Investigator that the patient should not participate in the study&#xD;
                  if the patient is unlikely to comply with study procedures, restrictions, and&#xD;
                  requirements.&#xD;
&#xD;
              15. Any disease or condition that, in the opinion of the Investigator, would&#xD;
                  compromise the safety of the patient or interfere with study assessments.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chinese Academy of Medical Science</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jie Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Danqing Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wenxiang Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sichuan Cancer Hospital</name>
      <address>
        <city>Chendu</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yongtao Han</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sichuan Provincial People's Hospital</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Gang Feng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qingchen Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Consonancy Hospital</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chun Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Guibin Qiao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University School Of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ying Chai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Yunnan Province</name>
      <address>
        <city>Kunming</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hao Peng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yunnan Cancer Hospital</name>
      <address>
        <city>Kunming</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yunchao Huang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>JiangXi Cancer Hospital</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yukang Kuang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Bentong Yu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Feng Jiang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Provincial People's Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Liang Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ningbo Medical Center Li Huili Hospital</name>
      <address>
        <city>Ningbo</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Weiyu Shen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qingdao Municipal Hospital</name>
      <address>
        <city>Qingdao</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ShangHai Chest Hospital ShangHai JiaoTong University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wentao Fang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ShangHai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuming Zhu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hongxu Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center</name>
      <address>
        <city>Shenzhen</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhentao Yu</last_name>
    </contact>
    <contact_backup>
      <last_name>Jianhua Chang</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hebei Cancer Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ziqiang Tian</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital，Sichuan University</name>
      <address>
        <city>Sichuan</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lunxu Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Haitao Ma</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thoracic Surgery Department Of The ShanXi Provincial Cancer Hospital</name>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Quan Sun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Chest Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Daqiang Sun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weifang People's Hospital</name>
      <address>
        <city>Weifang</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Guohua Yu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Deyao Xie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan Union Hospital Of China</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yongde Liao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Junke Fu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yu Qi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Tumor Hospital of Xinjiang Medical University</name>
      <address>
        <city>Ürümqi</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Dili A</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>April 10, 2021</last_update_submitted>
  <last_update_submitted_qc>April 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Shugeng Gao</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

